The US Blood Banking Market through 2013

Publication Date	September 2009
Publisher	Venture Planning Grp.
Product Type	Report
Pages	460
ISBN Number	not applicable
Product Code	VEP00276

Buy this product or for assistance call +44 20 7060 7474

PDF £4,090.00$6803 | €4578

FAX Order above formats by FAX

Summary

This report presents a comprehensive analysis of the US blood banking market, including:

Major issues pertaining to the US blood banking practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Specifically, the study explores the impact of anticipated changes in government regulations, trends in complicated surgeries, birth rate and other key issues.
Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in US community and regional blood centers, hospitals, commercial laboratories, and plasma fractionation facilities.
Annual placements and installed base estimates for major automated and semiautomated analyzers.
Review of current instrumentation technologies, and a feature comparison of over 20 analyzers.
Ten-year reagent and instrument sales forecasts.
Sales and market shares of leading reagent and instrument suppliers
Review of current and emerging technologies, and their potential market applications.
Product development opportunities for instruments ,consumables, and auxiliary products.
Profiles of major current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Business opportunities and strategic recommendations for suppliers.

Content

A. Major Blood Typing, Grouping and Infectious Disease Screening Tests
- 1. Blood Typing and Grouping Tests
- a. ABO
- b. Antibody Panels
- c. Antibody Screening
- d. Antigen Typing
- e. Antiglobulin Test
- f. Crossmatch
- g. HLA Typing
- h. Rh
- i. Other Blood Groups
2. Infectious Disease Screening Tests
- a. AIDS
- Structure and Composition
- Classification
- HIV-2 Infection
- Origin of AIDS
- Animal Lentivirus Systems
- Virus Receptors
- HIV Infections in Humans
- Pathogenesis & Pathology
- Overview of Course of HIV Infection
- CD4T Lymphocytes and Memory Cells
- Monocytes and Macrophages
- Lymphoid Organs
- Neural Cells
- Viral Coinfections
- Clinical Findings
- Plasma Viral Load
- Pediactric AIDS
- Neurologic Disease
- Opportunistic Infections
- Protozoa
- Fungi
- Bacteria
- Viruses
- Cancer
- Immunity
- Laboratory Diagnosis
- Virus Isolation
- Serology
- Detection of Viral Nucleic Acid or Antigens
- Epidemiology
- Worldwide Spread of AIDS
- United States
- Routes of Transmission
- Prevention, Treatment, And Control
- Antiviral Drugs
- Vaccines Against HIV
- Transmission of HIV in Blood Products
- HIV Transmission in Transplant and
- Artificial Insemination Recipients
- Diagnostic Tests
- Enzyme Immunoassay Interpretation
- Specificity, Sensitivity, and Predictive
- Value of Enzyme Immunoassay
- Competition Assays
- Western Blot Technique
- ImmunoFluorescence Assay (IFA)
- Radioimmunoprecipitation
- HIV1/HIV2 Combination Testing
- Methods of HIVAntigen Detection
- Antigen Assays and Blood Screening
- Urine Tests
- DNA Probes
- Overview
- Quantitative Polymerase Chain Reaction
- In Situ PCR
- Needed Improvements
- Viral Load/Drug Resistance Testing
- Genotype and Phenotype Testing
- Blood Banking Considerations
- b. Hepatitis
- Hepatitis A
- Hepatitis B
- Structure and Composition
- Replication of Hepatitis B Virus
- Hepatitis C
- Hepatitis D (Delta Hepatitis)
- Hepatitis E
- Hepatitis G
- Hepatitis Virus Infections In Humans
- Pathology
- Clinical Findings
- Laboratory Features
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- VirusHost Immune Reactions
- Epidemiology
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D (Delta Agent)
- Vaccines and Drugs
- c. Cytomegalovirus
- Background
- Chorioretinitis
- Gastrointestinal
- Central Nervous System Disease
- Diagnostic Tests
- Vaccines and Drugs
- d. Syphilis
- Background
- Diagnostic Tests
- Vaccines and Drugs
- e. West Nile Virus
- Background
- Clinical Syndromes
- Diagnostic Tests
- Vaccines and Drugs
- f. Parvovirus B19
- Microbiology
- Epidemiology
- Clinical Syndromes
- Erythema Infectiosum Slapped (cheek)
- Adult Polyarthropathy
- Transient Aplastic Crisis
- Transient Pancytopenia
- Red Cell Aplasia in the Immunocompromised
- Perinatal Infections
- Diagnosis
- Treatment
- g. CreutzfeldtJakob's Disease
- Background
- Transmission
- Diagnostic Tests
- Major Commercial and Academic Players
- Bayer
- Disease Sciences/BioTec Global
- Imperial College School of Medicine
- OrthoClinical Diagnostics
- Pall
- ProMetic Life Sciences
- Proteome Sciences/Idexx
- QOne Biotech
- Serono
- U.S. Agricultural Research Service
- Drugs
- Vaccines
- h. Malaria
- i. Chagas Disease
- j. Babesiosis
- 3. Pathogen Reduction
- 4. Leukocyte Reduction
- Background
- Methods
B. Instrumentation Review
- Introduction
- 1. Abbott Prism
- 2. Abbott Quantum II
- 3. Abbott Commander
- 4. BioMeriuex BacT/Alert
- 5. Dade Behring Quadriga
- 6. Dade Behring BEP 2000
- 7. Grifols Diana
- 8. Immucor ABS2000
- 8. Immucor Galile
- 10. Immucor Rosys Plato
- 11. Olympus PK7100
- 12. Olympus PK7200
- 13. Olympus PK80
- 14. Olympus BloodTrack Courier
- 15. Ortho AutoVue/ProVue
- 16. Ortho Summit Processor
- 17. Tecan ELPHAtyper
- 18. Tecan Hemotyper
- 19. Tecan MegaFlex
- 20. Tecan MiniSwift
C. Major in Vitro Diagnostic Technologies
- And Their Potential Applications
- 1. Molecular Diagnostics
- a. Overview
- b. NAT
- 2. Monoclonal and Polyclonal Antibodies
- 3. Immunoassays
- a. Technological Principle
- b. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Enzyme Amplification
- c. Fluorescent Immunoassays
- Fluorescence Polarization
- d. Luminescence
- Chemiluminescence
- Bioluminescence
- e. Latex Agglutination
- f. Immunoprecipitation
- 4. Microtitration Plates
- 5. Microcomputers
- 6. Automation
- 7. Lasers
- 8. Robotics
- 9. Artificial Intelligence
- 10. Synthetic Red Cell Substitutes
- 11. Genetically Engineered Blood Components
- a. Albumin
- b. Factor VIII
- c. Alpha2 Antiplasmin
- d. Antithrombin III
- e. Factor IX
- f. Von Willebrand's Factor
- g. Fibrinogen
- h. tPA
- 12. Blood Preservation
- 13. Autologous Blood Transfusion/Freezing
- D. Worldwide Market Overview
- 1. Business Environment
- 2. Market Structure
- 3. Market Size and Growth
U.S.A.
- A. Executive Summary
- B. Business Environment
- 1. Overview
- 2. Health Care Expenditures
- 3 Cost Consciousness
- 4. Reimbursement
- 5. Industry Consolidation
- 6. Managed Care
- a. HMO
- b. PPO
- 7. Hospitals
- 8. Admissions
- 9. Length of Stay
- 10. Industry Diversification
- 11. Physician Demographics
- 12. Population Aging
- a. Chronic Illnesses
- b. Disease Incidence
- c. Susceptibility to Iatrogenesis
- d. Multiple Illness Cases
- 13. Laboratory Regulations
- 14. FDA Reform
Major Product Development Opportunities
- A. Blood Typing and Grouping
- B. Infectious Disease Screening
- C. Auxiliary
Alternative Market Penetration Strategies
- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
Potential Market Entry Barriers and Risks
- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge And Limitations
- E. Patent Protection
- F. Regulatory Constraints
Competitive Assessments
- Abbott
- Beckman Coulter
- Biokit
- BioMerieux
- BioRad
- Bioscot
- Biotest
- Chiron
- Diagast
- Diamed
- DiaSorin
- Fujirebio
- GenProbe
- Gradipore
- Grifols
- ImmucorGamma
- Innogenetics
- Orchid Biosciences
- OrthoClinical Diagnostics
- Proteome Sciences
- Roche
- Siemens
- Tecan
Appendix: Assumed Currency Exchange Rates